Chemotherapy for non-small cell lung cancer (NSCLC) patients includes molecular targeted inhibitors, cell-killing anticancer agents, and immune-checkpoint inhibitors represented by programmed death 1 (PD-1) / programmed death ligand 1 (PD-L1) inhibitors [1]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.